EULAR Public Affairs: Position papers
EULAR Position Paper on Innovation in Healthcare
(2019) Innovation in healthcare has the potential to substantially reduce the burden of chronic diseases and ensure the sustainability of European health and social care systems. Download pdf
EULAR Position Paper on Biosimilars
(2018) New studies and data regarding the use of biosimilars, as well as feedback received from patient organisations and in particular from PARE organisations, indicate a need to update EULAR PARE’s 2015 position paper.
EULAR Position Paper on Horizon Europe
(2018) The European League Against Rheumatism (EULAR) welcomes the European Commission’s proposal on Horizon Europe and supports the Commission’s efforts in strengthening the social and economic impact of EU’s investment in research and innovation.
EULAR Position Paper on Health and Safety at work
(2018) Rheumatic and musculoskeletal diseases (RMDs) are the main health problem in the workplace in Europe. Every year, inadequate working conditions (in particularergonomic related risks) affect the musculoskeletal health and wellbeing of millions of EU citizens while having an equally detrimental effect on economies and societies. Improving working conditions and workplaces is crucial for preventing work-related risk factors, as well as to facilitate the active participation in the labour market of people with these and other conditions.
EULAR Position Paper on Access to health care for people with rheumatic and musculoskeletal diseases (RMDs)
(2015) Access to quality health care is one of the main concerns for people with rheumatic and musculoskeletal diseases (RMDs) and other chronic conditions in European countries. Despite the principle implied in EU law and most national legislations that health services should be accessible to all, European citizens still have to cope with a number of access barriers.
PARE position paper on biosimilars
(2015) The availability of reliable, up-to-date information about biosimilars is crucial to the patient's understanding of biosimilars. Patients and patient organisations need evidence-based information that allows them to make informed decisions and choices about treatment and patient care.
Protecting health and scientific research in the data protection regulation (2012/0011(COD)). Position of non-commercial research organisations and academics
(2014) Together with a number of European scientific societies, EULAR signed a statement calling the EU Council and the European Commission to oppose the European Parliament amendments to the Commission’s proposal for a new EU data protection regulation, particularly amendments to articles 81 and 83. These articles established specific provisions for the storage and processing of personal data in health care as well as in statistic and medical research activities.
EULAR contribution to the EU reflection on chronic diseases
(2012) This paper presents the EULAR contribution to the consultation on chronic diseases the European Commission launched in 2012. The document exposes the EULAR position regarding different issues: health promotion and prevention of chronic diseases; health care; research; information and health technology; and the role of EU, Member States and stakeholders in addressing chronic diseases.
EULAR position paper on Horizon 2020
(2011) EULAR issued a position paper on Horizon 2020. The aim of this document was to raise awareness on the need to further support research and innovation in RMDs, given the enormous burden of these conditions. The paper also indicates and suggests priority research topics that should receive the attention of funders.
Download pdf brief
What are RMDs?
Read the EULAR Q&A on Rheumatic & Muscuoloskeletal diseases (RMDs) to find out what they - and what problems they pose to individuals and society. Click here.